Tissue Collection for Drug Screening and Bioanalysis

NCT04852354 | Recruiting

• 1 other identifier: 20-01021289
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to test how they respond to different drugs. This research will help improve treatment options and identify new targets for therapy.

Conditions

Central Nervous System Tumor

Outcome Measures

Primary Outcomes (1)

• Evaluating and characterizing the genetic, immunohistochemical, cellular, and molecular profiles of pediatric neoplastic lesions

  To develop patient-derived tissue cell lines and xenografts

  Through study completion, average 1-3 years

Study Arms (4)

Cohort 1: Tumor patients undergoing neurosurgery

Samples of tumor tissue, blood, CSF, saliva, skull, and dura will be taken during neurosurgery from tumor patients meeting the inclusion criteria.

Parents of tumor patients

Saliva samples will be taken from parents of tumor patients meeting the inclusion criteria.

Cohort 2: Non-Tumor patients undergoing neurosurgery

Blood and CSF samples will be taken from non-tumor patients meeting the inclusion criteria.

Cohort 3: Autopsy tumor tissue donation

Post-mortem biospecimens such as whole brain, spinal cord, biofluids (e.g., cerebrospinal fluid and blood) and skin biopsy will be collected through autopsy donation from brain tumor patients meeting the inclusion criteria.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a central nervous system tumors. Parents of patients with CNS tumors.

You may qualify if:

• Subject has presented with a suspected/confirmed neoplastic CNS lesion and is undergoing a neurosurgical procedure in which CNS tissue and/or tumors associated with this tissue will be removed.
• There must be tissue available in excess of that required by neuropathology for diagnostic purposes.
• Subject of all ages included.
• Subjects who are pregnant can be included.
• Subjects who are neonates (0-4 weeks) can be included.
• Subject is between 4 weeks and 21 years of age and is undergoing a neurosurgical procedure at WCMC.
• Subject does not have a CNS tumor diagnosis.
• Subject should not be pregnant at the time of enrollment.
• Subject of all ages included
• Subject has been diagnosed with a neoplastic CNS lesion at the time of passing.
• Subjects who are pregnant can be included.
• Subjects who are neonates (0-4 weeks) can be included.
• Subject is the biological parent of a patient undergoing/ who underwent a neurosurgical procedure in which CNS tissue and/or tumors associated with this tissue will be/ was removed.
• Subject is the biological parent of patient enrolled in cohort 1.
• Subject is not pregnant at the time of enrollment.

Sponsors & Collaborators

• Weill Medical College of Cornell University: lead

Study Sites (1)

Weill Cornell Medicine

New York, New York, 10021, United States

RECRUITING

Related Publications (1)

• Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse J, Pisapia DJ, Chan TA, Lyden DC, Bromberg JF, Greenfield JP. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clin Cancer Res. 2017 Jun 15;23(12):3109-3119. doi: 10.1158/1078-0432.CCR-16-1508. Epub 2016 Dec 30.

  PMID: 28039266 BACKGROUND

MeSH Terms

Conditions

Central Nervous System Neoplasms

Condition Hierarchy (Ancestors)

Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Nervous System Diseases

Study Officials

• Jeffrey Greenfield, M.D.

  Weill Medical College of Cornell University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jeffrey Greenfield, M.D.

CONTACT

212-746-2363; jpgreenf@med.cornell.edu

Pediatric Neurosurgery

CONTACT

212-746-2363; pediatricneurosurgery@med.cornell.edu

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2021
• First Posted: April 21, 2021
• Study Start: July 22, 2020
• Primary Completion (Estimated): July 22, 2029
• Study Completion (Estimated): July 22, 2029
• Last Updated: December 17, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)